HBL - Hadasit Bio-Holdings Ltd (TASE: HDST-M)
Health Care · Biotechnology · IL
₪0.65
+8.00% today · +27.1% 1Y
HBL - Hadasit Bio-Holdings Ltd (TASE: HDST-M) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.40M.
Over the last twelve months the share price has gained 27.1%, trading between 0.30 and 0.85.
Tweenvest scores HBL - Hadasit Bio-Holdings Ltd across four factors: quality 28/100, value 60/100. Its strongest factor is value.
HDST-M price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.40M
- Revenue (TTM)
- $35.92K
- P/E
- —
- EPS
- -0.13
- Dividend yield
- —
- Beta (5Y)
- -0.49
- 52-week high
- ₪0.85
- 52-week low
- ₪0.30
- Avg volume (3M)
- —
- Shares outstanding
- 11.09M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.97 | +0.58% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.